TY  - JOUR
AU  - Paiva, Bruno
AU  - Puig, Noemi
AU  - Cedena, Maria-Teresa
AU  - Rosiñol, Laura
AU  - Cordón, Lourdes
AU  - Vidriales, María-Belén
AU  - Burgos, Leire
AU  - Flores-Montero, Juan
AU  - Sanoja-Flores, Luzalba
AU  - Lopez-Anglada, Lucia
AU  - Maldonado, Roberto
AU  - de la Cruz, Javier
AU  - Gutierrez, Norma C
AU  - Calasanz, Maria-Jose
AU  - Martin-Ramos, Maria-Luisa
AU  - Garcia-Sanz, Ramón
AU  - Martinez-Lopez, Joaquin
AU  - Oriol, Albert
AU  - Blanchard, María-Jesús
AU  - Rios, Rafael
AU  - Martin, Jesus
AU  - Martinez-Martinez, Rafael
AU  - Sureda, Anna
AU  - Hernandez, Miguel-Teodoro
AU  - de la Rubia, Javier
AU  - Krsnik, Isabel
AU  - Moraleda, Jose-Maria
AU  - Palomera, Luis
AU  - Bargay, Joan
AU  - Van Dongen, Jacques J M
AU  - Orfao, Alberto
AU  - Mateos, Maria-Victoria
AU  - Blade, Joan
AU  - San-Miguel, Jesús F
AU  - Lahuerta, Juan-José
AU  - GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group
PY  - 2019
DO  - 10.1200/JCO.19.01231
UR  - http://hdl.handle.net/10668/14743
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to...
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bortezomib
KW  - Clinical Trials, Phase III as Topic
KW  - Dexamethasone
KW  - Female
KW  - Flow Cytometry
KW  - Humans
KW  - Lenalidomide
KW  - Longitudinal Studies
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Neoplasm, Residual
KW  - Randomized Controlled Trials as Topic
TI  - Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
TY  - research article
VL  - 38
ER  -